Ashley Sumrall, MD, FACP, discusses the range of unmet treatment needs for patients with gliomas, the impacts that disease classification evolutions have had on glioma diagnosis and management, and ongoing research with the DRD2 dopamine receptor–targeted agent ONC201 in patients with H3K27M-mutated disease.
Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.
Clinical studies reveal extended survival in diffuse midline glioma patients receiving ONC201 treatment; research also explains the underlying mechanism of the drug’s success. For the first time, a potential drug candidate has been identified by researchers that show promise in improving outcomes f
Research Uncovers Survival Boost for Incurable Brain Tumor miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.